TY - JOUR
T1 - Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States
AU - Bartsch, S. M.
AU - McKinnell, J. A.
AU - Mueller, L. E.
AU - Miller, L. G.
AU - Gohil, S. K.
AU - Huang, S. S.
AU - Lee, B. Y.
N1 - Publisher Copyright:
© 2016 European Society of Clinical Microbiology and Infectious Diseases
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Objectives The Centers for Disease Control and Prevention considers carbapenem-resistant Enterobacteriaceae (CRE) an urgent public health threat; however, its economic burden is unknown. Methods We developed a CRE clinical and economics outcomes model to determine the cost of CRE infection from the hospital, third-party payer, and societal, perspectives and to evaluate the health and economic burden of CRE to the USA. Results Depending on the infection type, the median cost of a single CRE infection can range from $22 484 to $66 031 for hospitals, $10 440 to $31 621 for third-party payers, and $37 778 to $83 512 for society. An infection incidence of 2.93 per 100 000 population in the USA (9418 infections) would cost hospitals $275 million (95% CR $217–334 million), third-party payers $147 million (95% CR $129–172 million), and society $553 million (95% CR $303–1593 million) with a 25% attributable mortality, and would result in the loss of 8841 (95% CR 5805–12 420) quality-adjusted life years. An incidence of 15 per 100 000 (48 213 infections) would cost hospitals $1.4 billion (95% CR $1.1–1.7 billion), third-party payers $0.8 billion (95% CR $0.6–0.8 billion), and society $2.8 billion (95% CR $1.6–8.2 billion), and result in the loss of 45 261 quality-adjusted life years. Conclusions The cost of CRE is higher than the annual cost of many chronic diseases and of many acute diseases. Costs rise proportionally with the incidence of CRE, increasing by 2.0 times, 3.4 times, and 5.1 times for incidence rates of 6, 10, and 15 per 100 000 persons.
AB - Objectives The Centers for Disease Control and Prevention considers carbapenem-resistant Enterobacteriaceae (CRE) an urgent public health threat; however, its economic burden is unknown. Methods We developed a CRE clinical and economics outcomes model to determine the cost of CRE infection from the hospital, third-party payer, and societal, perspectives and to evaluate the health and economic burden of CRE to the USA. Results Depending on the infection type, the median cost of a single CRE infection can range from $22 484 to $66 031 for hospitals, $10 440 to $31 621 for third-party payers, and $37 778 to $83 512 for society. An infection incidence of 2.93 per 100 000 population in the USA (9418 infections) would cost hospitals $275 million (95% CR $217–334 million), third-party payers $147 million (95% CR $129–172 million), and society $553 million (95% CR $303–1593 million) with a 25% attributable mortality, and would result in the loss of 8841 (95% CR 5805–12 420) quality-adjusted life years. An incidence of 15 per 100 000 (48 213 infections) would cost hospitals $1.4 billion (95% CR $1.1–1.7 billion), third-party payers $0.8 billion (95% CR $0.6–0.8 billion), and society $2.8 billion (95% CR $1.6–8.2 billion), and result in the loss of 45 261 quality-adjusted life years. Conclusions The cost of CRE is higher than the annual cost of many chronic diseases and of many acute diseases. Costs rise proportionally with the incidence of CRE, increasing by 2.0 times, 3.4 times, and 5.1 times for incidence rates of 6, 10, and 15 per 100 000 persons.
KW - CRE
KW - Carbapenem-resistant Enterobacteriaceae
KW - Cost
KW - Economic burden
KW - Model
UR - http://www.scopus.com/inward/record.url?scp=85002873168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85002873168&partnerID=8YFLogxK
U2 - 10.1016/j.cmi.2016.09.003
DO - 10.1016/j.cmi.2016.09.003
M3 - Article
C2 - 27642178
AN - SCOPUS:85002873168
SN - 1198-743X
VL - 23
SP - 48.e9-48.e16
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 1
ER -